News and Announcements
Imugene Announces New Strategic Partnership with the Baker Institute
- Published February 28, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX:IMU) incurred expenditure of $2.27m, which was offset in large part by an expected rebate of $0.77m under the Australian Governments R&D tax incentive scheme. The majority of expense, being $1.65m, were incurred on research and development, with the balance being payroll and administration costs.
KEY TAKEAWAYS:
- New strategic partnerships with the Baker Institute investigating the opportunities for small molecules in immune-oncology.
- Four new mimotope patents filed to expand Imugene pipeline into B-cell vaccine compositions and franchise.
- Successful $3.2M private placement with sophisticated and institutional investors.
- Cash and cash equivalents 31 December 2016: Up 41% on pcp to $3.8M.
- Phase 1b/2 trial in patients with metastatic gastric cancer to recruit in 2017.
- Loss for the 6 months to 31 December 2016: Up 45.00% on previous comparable period (‘pcp’) to $1.49M.
Imugene is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
